Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Trial of Personalized Cancer Treatment Begins in Oxford

Published: Tuesday, March 18, 2014
Last Updated: Tuesday, March 18, 2014
Bookmark and Share
Phase I trial in Oxford will investigate a new drug, called CXD101.

The first human trial of a pioneering personalized cancer treatment developed at Oxford University will begin this week, with the potential to tackle a wide range of late-stage cancers.

A major challenge in drug development is that all cancer patients respond differently to treatment, making it difficult to know how best to treat each patient. For the first time, a phase I trial in Oxford will investigate not only a new drug, called CXD101, but also a new test to predict which patients could be successfully treated by this class of drug.

'When patients' cancers do not respond to a treatment, this can cost tens of thousands of pounds and cause patients to suffer side effects for nothing,' said lead researcher Professor Nick La Thangue of Oxford University's Department of Oncology. 'Personalized medicine promises to prevent this by predicting how well a patient will respond to a drug before administering it and this is exactly what this trial will do. This is really the shape of things to come, and avoids the problem of testing drugs on patients who have little chance of benefiting from the treatment.'

The drug and associated test were first developed at Oxford University and are now being developed by spin-outs Celleron Therapeutics and Oxford Cancer Biomarkers, founded by Professors La Thangue and David Kerr and set up by the University's technology transfer company Isis Innovation. The new clinical trial is being carried out by Oxford University Hospitals NHS Trust.

The test measures levels of a protein called HR23B that could determine the effectiveness of CXD101 and similar drugs. The trial will involve 30-40 cancer patients, the first set of whom will be given increasing doses of CXD101 to determine the most effective dose. The second cohort of patients will then be tested for HR23B, and those with high levels of the protein will be treated with the best dose of CXD101.

CXD101 is a next-generation histone deacetylase (HDAC) inhibitor, a class of drug that kills cancer cells by blocking the vital functions of HDAC enzymes. HDAC enzymes are important for cell multiplication, migration and survival, so blocking them can stop tumours from growing and spreading, and even kill cancer cells entirely.

'HDAC inhibitors have had limited success in the past, but CXD101 works in a completely new way and has great potential to treat many different cancers,' said Professor La Thangue. 'Our previous research suggests that high levels of the HR23B protein make tumours more vulnerable to HDAC inhibitors, so we will now be putting this into practice to identify the patients who are most likely to benefit from CXD101. Any cancer could be high in HR23B, from breast cancers to blood cancers, so we are screening a broad range of patients to identify anyone who might benefit.'

The trial is a unique collaboration between Oxford University, Oxford University Hospitals NHS Trust, Celleron Therapeutics, Oxford Cancer Biomarkers and the ECMC (Experimental Cancer Medicine Centre) network. The Oxford ECMC, jointly funded by Cancer Research UK and the National Institute for Health Research, is led by Mark Middleton, Professor of Experimental Cancer Medicine at Oxford University's Department of Oncology, clinical lead for the CXD101 trial.

'This trial marks a lot of firsts - the first time the hospital has sponsored a trial of a new agent, the first time we will trial a predictive test along with a new drug, the first time CXD101 will be taken by patients, and even the development of the trial is new,' said Professor Middleton. 'We are working closely with the spin-outs to deliver the trial using a new model that allows the companies to set up the trial faster. This risk-sharing model encourages innovation, accelerates drug development and will bring benefits to UK plc in the long run.'


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Type 2 Diabetes Genetics Revealed
The largest study of its kind into type 2 diabetes has produced the most detailed picture to date of the genetics underlying the condition.
Wednesday, July 13, 2016
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Friday, June 17, 2016
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Friday, May 27, 2016
Origin of a Species
A study by researchers at the Wellcome Trust Centre for Human Genetics at Oxford University has uncovered the key role played by a single gene in how groups of animals diverge to form new species.
Monday, February 15, 2016
Why we Still Don’t Have Personalised Medicine
15 years after sequencing the human genome we still do not have the promised personalised medicine, why is this?
Friday, December 04, 2015
Mini DNA Sequencer’s Data Belies its Size
A miniature DNA sequencing device that plugs into a laptop and was developed by Oxford Nanopore has been tested by an open, international consortium, including Oxford University researchers.
Tuesday, October 20, 2015
New Insight into Recombination and Sex Chromosomes
Not only does the platypus have some odd physical features, an updated version of its genome has also underscored the unusual genetic characteristics that it harbors.
Tuesday, May 12, 2015
Key Molecule Could Reveal Many Cancers Early On
A technique for monitoring high levels of a protein found in many pre-cancerous cell types – including breast, lung and skin cancer – could be used to detect cancer early.
Wednesday, November 07, 2012
TB Vaccine Enters new Clinical Trials Health
The MVA85A vaccine, developed at the University of Oxford, is to enter Phase IIb proof-of-concept clinical trials.
Thursday, April 23, 2009
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Mystery of Early Embryonic Development Solved
Breakthrough genomics technique can be used to map epigenetic marks across the genome using fewer cells and will benefit cancer research
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!